Zhejiang ACEA Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 2015-11-23
- Employees
- -
- Market Cap
- -
- Website
- https://www.aceapharma.com
Clinical Trials
7
Active:0
Completed:5
Trial Phases
2 Phases
Phase 1:6
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (85.7%)Phase 3
1 (14.3%)A Bioequivalence Trial of Fasting Single Oral STI-1558 Capsule in Healthy Chinese Subjects
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06044233
- Locations
- 🇨🇳
Zhejiang Xiaoshan Hospital, Hangzhou, China
A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT05947344
- Locations
- 🇨🇳
the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
[14C] Study on Mass Balance and Biotransformation of STI-1558 in Healthy Chinese Adult Male Subjects
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- Drug: [14C]STI-1558
- First Posted Date
- 2023-03-03
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05754411
- Locations
- 🇨🇳
Beijing Gaobo Boren Hospital, Beijing, China
Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19)
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
- Target Recruit Count
- 1218
- Registration Number
- NCT05716425
- Locations
- 🇨🇳
Beijing Ditan Hospital, Capital Medical University, Beijing, China
🇨🇳Shenzhen Third People 's Hospital, Shenzhen, China
A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558
Phase 1
Completed
- Conditions
- COVID-19 Pneumonia
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT05685719
- Locations
- 🇨🇳
Zhejiang Xiaoshan Hospital, Hangzhou, Zhejiang, China
- Prev
- 1
- 2
- Next
News
No news found